- Home
- AMZE vs SNSE Comparison
AMZE vs SNSE Comparison
Compare AMZE & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMZE | SNSE |
|---|---|---|
| Founded | 2019 | 2005 |
| Country | United States | United States |
| Employees | 4 | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3M | 12.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AMZE | SNSE |
|---|---|---|
| Price | $0.13 | $27.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.00 | ★ $65.00 |
| AVG Volume (30 Days) | ★ 2.6M | 32.1K |
| Earning Date | 05-19-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,986.62 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.26 |
| 52 Week High | $11.76 | $36.76 |
Technical Indicators
Market Signals| Indicator | AMZE | SNSE |
|---|---|---|
| Relative Strength Index (RSI) | 29.60 | 42.29 |
| Support Level | $0.12 | $25.94 |
| Resistance Level | $0.20 | $35.42 |
| Average True Range (ATR) | 0.02 | 2.67 |
| MACD | 0.00 | -0.44 |
| Stochastic Oscillator | 5.01 | 14.66 |
Price Performance
Historical ComparisonAbout AMZE Amaze Holdings Inc.
Amaze Holdings Inc is a software company dedicated to empowering creators by providing comprehensive software solutions and services that facilitate e-commerce, social commerce, integrated commerce selling experiences, and the distribution of a premium wine brand. The group offers an end-to-end, creator-powered commerce platform offering tools for seamless product creation, modern e-commerce solutions, and scalable managed services.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).